Medical

Tiziana Life Sciences has announced plans for development of its foralumab intranasal anti-CD3 monoclonal antibody for two additional indications, Type 1 diabetes and Alzheimer's disease. Tiziana said that it is initiating a development program for diabetes and that it plans to submit an IND for clinical development of foralumab in patients with Alzheimer's in the … [Read more...] about Tiziana announces plans for development of intranasal foralumab for diabetes, Alzheimer’s

Vyne Therapeutics said that an inhaled formulation of its VYN201 pan-BET inhibitor significantly reduced lung fibrosis and hydroxyproline levels in a mouse model of idiopathic pulmonary fibrosis (IPF) at doses of 0.5 mg/ml and 1 mg/ml, and functional lung volume and blood oxygen saturation were significantly improved. A topical formulation of VYN201 is currently in … [Read more...] about Vyne announces preclinical data for inhaled VYN201 in mouse model of IPF

Leyden Laboratories has initiated a Phase 1 trial of its intranasal PanFlu CR9114 anti-hemagglutinin stem human antibody in healthy volunteers, the company said. In July 2021, Leyden Labs announced that it had partnered with Nanopharm on development of intranasal formulations for Phase 1 studies. According to Leyden Labs, preclinical studies of CR9114 in animal models … [Read more...] about Leyden Labs initiates Phase 1 trial of PanFlu CR9114 nasal spray

Renovion has initiated a Phase 3 clinical study of its ARINA-1 inhaled glutathione / bicarbonate / ascorbic acid for the treatment of bronchiolitis obliterans syndrome (BOS) following bilateral lung transplant. ARINA-1 recently received Fast Track designation for that indication. Plans for the Phase 3 trial were announced in August 2022. According to the company, the … [Read more...] about Renovion initiates Phase 3 trial of ARINA-1 nebulized mucolytic in patients who have had a bilateral lung transplant

Tonix Pharmaceuticals said that it will reduce enrollment in the recently initiated Phase 2 PREVENTION study of TNX-1900 intranasal potentiated oxytocin in migraine patients from about 300 subjects to about 150 subjects, with a goal of providing topline data by the end of 2023. As part of the company's efforts to "streamline" two of its clinical trials, a Phase 3 … [Read more...] about Tonix will modify Phase 2 study of TNX-1900 intranasal potentiated oxytocin for the treatment of migraine

US-based startup Pocket Naloxone said that a human factors study of its NaxSwab OTC naloxone nasal swab demonstrated that the swab could be used effectively in a simulated emergency by a wide range of people, including adolescents. The company said that 41 of 45 lay people and 15 of 15 healthcare professionals who participated in the study were able to successfully … [Read more...] about Pocket Naloxone announces results of human factors study of its NaxSwab OTC naloxone nasal swab

Nuance Pharma has initiated the ENHANCE - China Phase 3 study of nebulized ensifentrine in mainland China, the company said. Nuance obtained the rights to develop and market ensifentrine in China, Macau, Taiwan, and Hong Kong from Verona Pharma in 2021 and in August 2022, the company said that the Chinese Center for Drug Evaluation had approved its IND for Phase 1 and … [Read more...] about Nuance Pharma initiates Phase 3 trial of nebulized ensifentrine for COPD in China

Tiziana Life Sciences says that after receiving feedback from the FDA following a Type C meeting, the company plans to move forward with a Phase 2 trial of intranasal foralumab, a human anti-CD3 mAb, in patients with non-active secondary progressive multiple sclerosis. In September 2019, Tiziana announced results from its Phase 1 trial of intranasal foralumab. Since … [Read more...] about Tiziana announces plans for Phase 2 trial of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis 

Avalyn Pharma has published data from its Phase 1b ATLAS study evaluating the safety of AP01 nebulized pirfenidone in patients with idiopathic pulmonary fibrosis over 72 weeks. In the article, the authors report that treatment-related adverse events were mild-to-moderate and less frequent than side effects associated with oral pirfenidone. They also reported that … [Read more...] about Avalyn reports data from Phase 1b study of AP01 inhaled pirfenidone in IPF patients